Table 3.
Multivariate analysis of prognostic factors in 965 patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation
| Overall Survival | Disease-Free Survival | ||||||
|---|---|---|---|---|---|---|---|
| Reference | HR | (CI 95%) | p | HR | (CI 95%) | p | |
| Age | 1.04 | 1.03–1.06 | 0.000 | 1.03 | (1.01–1.04) | 0.000 | |
| Sex | Female | 0.79 | 0.59–1.06 | 0.113 | 0.82 | (0.63–1.06) | 0.127 |
| cT | I-II | 1.58 | 0.88–2.84 | 0.127 | 1.18 | (0.74–1.88) | 0.495 |
| cN | 0 | 0.93 | 0.71–1.23 | 0.634 | 1.07 | (0.84–1.37) | 0.57 |
| Platelets count | < 300 × 109/L | 1.45 | 1.10–1.92 | 0.009 | 1.39 | (1.09–1.79) | 0.009 |
| Distance from anal verge | < 5 cms | 0.62 | 0.47–0.81 | 0.001 | 0.59 | (0.46–0.75) | 0.000 |
| Interval between CRT and Surgery | < 8 weeks | 1.04 | 0.78–1.38 | 0.798 | 1.18 | (0.91–1.54) | 0.213 |
HR hazard ratio, cT Clinical primary tumor stage, cN Clinical lymph node stage, CRT chemoradiation